Patients with relapsed/refractory acute myeloid leukemia or myelodysplastic neoplasms research hub

Safety, pharmacokinetics, and preliminary efficacy of BYON4413 in acute myeloid leukemia and myelodysplastic neoplasms.

This study is testing a new medicine called BYON4413 for people in the UK with acute myeloid leukaemia (AML) or myelodysplastic syndromes (MDS) that haven't responded to previous treatments. It's an early-stage study looking at safety and how the medicine works in the body.